checkAd

    IGI Laboritories - Unglaubliches Kursziel von Credit Suisse - 500 Beiträge pro Seite

    eröffnet am 09.01.15 11:55:37 von
    neuester Beitrag 30.09.16 10:07:53 von
    Beiträge: 33
    ID: 1.205.531
    Aufrufe heute: 0
    Gesamt: 3.643
    Aktive User: 0

    ISIN: US87960W2035 · WKN: A2P5KT
    0,0196
     
    EUR
    -56,44 %
    -0,0254 EUR
    Letzter Kurs 01.12.21 Frankfurt

    Werte aus der Branche Pharmaindustrie

    WertpapierKursPerf. %
    1,4850+72,88
    0,7500+50,00
    5,4000+33,33
    12,950+32,55
    0,7630+26,53
    WertpapierKursPerf. %
    3,8500-16,12
    7,5000-16,67
    1,9000-18,80
    1,4600-27,00
    3,6400-38,62

     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 09.01.15 11:55:37
      Beitrag Nr. 1 ()
      Habe gerade den alten Thread gefunden. Da der alte Thread geschlossen ist, musste einer neuer angelegt werden.
      Im alten Thread findet Ihr die Basisinformationen.
      Vielleicht war "panik" und die anderen 2007 etwas früh dran,
      aber manchmal lohnt es sich, Geduld zu haben. Seid Ihr noch dabei?
      Ich bin 2013 eingestiegen. Und dann habe ich heute das gefunden:

      http://www.mideasttime.com/brokerages-set-igi-laboratories-p…

      Ich meine Credit Suisse ist nicht irgendein Troll...
      2 Antworten
      Avatar
      schrieb am 09.01.15 20:33:43
      Beitrag Nr. 2 ()
      Antwort auf Beitrag Nr.: 48.733.739 von b1homann am 09.01.15 11:55:37
      die Kursziele sind schon extrem unterschiedlich
      interessant wäre dazu mal die Recherchen oder -eben- Begründungen dafür zu sehen

      prinzipiell hört sichs in der At an als ob die ein 'high risk high reward Pferd' im Stall haben -und die Einen dann auf keinen (großen)Erfolg setzen, die anderen aber auf einen Volltreffer
      wäre jetzt Eines der wenigen Szenarien das mir einfällt, was Sinn machen könnte
      Avatar
      schrieb am 04.02.15 15:35:27
      Beitrag Nr. 3 ()
      Hallo in die Runde,

      ich bin hier seit September letzten Jahres mit einer kleine Posi dabei, damals noch zu 6,90€.

      auf gute Zusammenarbeit

      -----------------------------------------------------------------------

      Over the last few years, IGI has been building a foundation for sustainable future growth through the expansion of its organic research and development efforts.

      IGI has submitted nineteen Abbreviated New Drug Applications, or (ANDAs) with the US FDA for generic topical pharmaceutical products. In March 2014, IGI received its first ANDA approval for the submission of its own, lidocaine hydrochloride USP 4% topical solution, which it had submitted in June 2012. In May 2014, IGI received tentative approval for diclofenac sodium 1.5% topical solution, which IGI plans to launch in March 2015.

      IGI believes the addressable market for the 22 ANDAs pending approval at the FDA in its pipeline exceed $500 million based on recent IMS data.

      Beyond the applications which the company has already submitted, our research and development team is currently working on a total of forty-three projects. IGI currently plans to submited 11 ANDAs in 2014.

      http://igilabs.com/index.php/what-we-do/pharmaceuticals/anda…

      Avatar
      schrieb am 04.02.15 17:36:53
      Beitrag Nr. 4 ()
      aus der Januar Präsentation

      ...22 ANDAs currently on file – including 11 filed in 2014, and plan to maintain tempo of 1-2 filings per month in 2015

      ...Currently market seven IGI products in 12 presentaAons (Diclofenac sodium will be launched in Spring 2015)

      http://igilabs.investorroom.com/download/WE+-+IGI+Laboratori…
      Avatar
      schrieb am 06.02.15 15:44:58
      Beitrag Nr. 5 ()
      BUENA, N.J., Feb. 6, 2015 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:15 pm ET on Monday, March 2, 2015 to discuss the 4th quarter 2014 results.

      The Company invites you to listen to the call by dialing 1-888-346-3479. International participants should call 1-412-902-4260. Canadian participants should call 1-855-669-9657. Participants should ask to be joined into the IGI Laboratories, Inc. call.

      This call is being webcast by MultiVu (a PR Newswire Company) and can be accessed in the Investor Relations Section of IGI's website at www.igilabs.com.

      http://igilabs.investorroom.com/2015-02-06-IGI-Laboratories-…

      Trading Spotlight

      Anzeige
      Rallye II. – Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…mehr zur Aktie »
      Avatar
      schrieb am 01.03.15 23:39:34
      Beitrag Nr. 6 ()
      Oppenheimer Boosts IGI Laboratories Price Target to $13.00 (IG)
      Publish date: Thu, 26 Feb 2015, 07:22 AM

      http://www.i3investor.com/servlets/fdnews/187052.jsp
      Avatar
      schrieb am 01.03.15 23:41:51
      Beitrag Nr. 7 ()
      IGI Laboratories To Hold Conference Call For 4th Quarter 2014 Results

      BUENA, N.J., Feb. 6, 2015 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:15 pm ET on Monday, March 2, 2015 to discuss the 4th quarter 2014 results.

      http://igilabs.investorroom.com/2015-02-27-IGI-Laboratories-…
      Avatar
      schrieb am 02.03.15 22:37:21
      Beitrag Nr. 8 ()
      IGI Laboratories Announces Fourth Quarter And Year End 2014 Results
      Mar 2, 2015

      Fourth Quarter and Year to Date 2014 Highlights

      •Total revenues of $13.7 million in the fourth quarter of 2014, an increase of 104% over the same quarter in 2013

      •Total revenues of $33.7 million for the year ended December 31, 2014, an increase of 85% over the same period in 2013

      •Total net revenues generated from the sale of IGI label generic topical pharmaceutical products for the three and twelve months ended December 31, 2014 of $10.5 million, and $19.8 million, respectively

      •Gross profit for the year ended December 31, 2014 equaled 50% as compared to 34% in the same period of 2013

      •IGI filed eleven Abbreviated New Drug Applications (ANDAs), in 2014 with the U.S. Food and Drug Administration (FDA)

      •Net income was $5.6 million in the fourth quarter of 2014, including a non-cash gain of $2.3 million, compared to $0.7 million in the same period in 2013

      •Net income was $5.3 million for the year ended December 31, 2014, including a non-cash gain of $2.3 million, compared to a net loss of $0.1 million for the year ended December 31, 2013

      http://igilabs.investorroom.com/2015-03-02-IGI-Laboratories-…


      Nachbörslich bis jetzt fast 4% runter
      Avatar
      schrieb am 26.03.15 19:12:18
      Beitrag Nr. 9 ()
      IGI Laboratories, Inc. Announces First ANDA Submission Of 2015

      BUENA, N.J., March 26, 2015 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, today announced it has submitted its first abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA) of 2015, which brings the Company's total number of ANDA submissions now pending at the FDA to twenty-three.

      Jason Grenfell-Gardner, President and CEO of the Company, commented, "On March 2, 2015, we committed to file at least twenty ANDAs in 2015. We believe the ANDA filed today has an addressable market of $20 million based on January 2015 data from IMS Health. We believe our current pipeline of submissions, exclusive of partnered submissions, pending approval by the FDA now has a combined addressable market of over $623 million based on January 2015 data from IMS Health."

      http://igilabs.investorroom.com/2015-03-26-IGI-Laboratories-…
      Avatar
      schrieb am 01.04.15 19:50:06
      Beitrag Nr. 10 ()
      ich glaub mit deiner empfehlung warst du leider zu spät. ig ist im märz zum ersten mal seit august 2013 wieder unter die 20-wochen-sma gerutscht. der aufwärtstrend ist wohl gebrochen.
      was außerdem negativ ist, der biotechindex kratzt am ath. die schwäche von ig ist also doppelt beunruigend. was kommt erst, wenn der biotechindex selbst schwäche zeigt?
      1 Antwort
      Avatar
      schrieb am 23.04.15 18:19:59
      Beitrag Nr. 11 ()
      Antwort auf Beitrag Nr.: 49.479.212 von steven_trader am 01.04.15 19:50:06IG scheint sich etwas zu fangen, aber "Erholung" würde ich das nicht nennen.
      Es fehlt halt an weiteren Zulassungen. Ich hab mal was von 3-4 Jahren von Einreichung bis Zulassung gelesen.
      Hast Du da nähere Infos drüber?
      Avatar
      schrieb am 29.04.15 17:51:33
      Beitrag Nr. 12 ()
      alles auf Anfang, vor einem Jahr Stand IG bei ca. 5$. Mal sehen wohin die Reise geht. Ich bin recht pessimistisch.

      IGI Laboratories Announces First Quarter 2015 Results
      http://igilabs.investorroom.com/2015-04-28-IGI-Laboratories-…
      Avatar
      schrieb am 30.06.15 23:37:29
      Beitrag Nr. 13 ()
      IGI Laboratories, Inc. Announces Fifth ANDA Submission Of 2015
      Jun 30, 2015

      http://igilabs.investorroom.com/2015-06-30-IGI-Laboratories-…


      ... IGI received tentative approval for diclofenac sodium 1.5% topical solution, which IGI plans to launch in Spring of 2015

      http://igilabs.com/index.php/what-we-do/pharmaceuticals/anda…
      Avatar
      schrieb am 09.07.15 20:17:30
      Beitrag Nr. 14 ()
      IGI Laboratories, Inc. Announces FDA Approval And Commercial Launch Of Diclofenac Sodium, 1.5%
      The Company Now Markets Seven Products in its Topical Portfolio
      Jul 9, 2015

      BUENA, N.J., July 9, 2015 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey-based specialty generic pharmaceutical company, today announced it has launched its seventh product, diclofenac sodium 1.5% topical solution, after receipt of the final approval from the U.S. Food and Drug Administration (FDA) for an abbreviated new drug application (ANDA). The Company now markets seven products in twelve presentations in an IGI label.

      Diclofenac sodium topical solution 1.5% is a nonsteroidal anti-inflammatory drug indicated for the treatment of the pain from osteoarthritis of the knee. Based on IMS Health data for May 2015, the total addressable market for this product is approximately $13.3 million. IGI originally submitted this ANDA to the FDA in December 2010.

      Jason Grenfell-Gardner, President and CEO of the Company, commented, "Today's action by the FDA represents our second drug approval for a product organically developed from beginning to end by our IGI team. In anticipation of this approval, we have already secured orders from our customers, and we are ready to fulfill these orders immediately.''

      ''We now have twenty-seven submissions, exclusive of our four partnered submissions, pending approval by the FDA, with a combined addressable market of over $939 million based on May 2015 data from IMS Health, and another fifteen more submissions planned before the end of this year. Our team continues to execute our R&D plan as part of our mission to become a leading player in the specialty generic prescription drug market."

      http://igilabs.investorroom.com/2015-07-09-IGI-Laboratories-…
      Avatar
      schrieb am 09.07.15 20:24:43
      Beitrag Nr. 15 ()
      IGI Laboratories To Hold Conference Call For 2nd Quarter 2015 Results

      BUENA, N.J., July 9, 2015 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:15 pm ET on Thursday, July 23, 2015 to discuss the 2nd quarter 2015 results.

      http://igilabs.investorroom.com/2015-07-09-IGI-Laboratories-…
      Avatar
      schrieb am 23.07.15 20:57:32
      Beitrag Nr. 16 ()
      Mal schauen, wo wir nach dem heutigen Conference Call stehen.
      Avatar
      schrieb am 24.07.15 15:25:50
      Beitrag Nr. 17 ()
      IGI Laboratories, Inc. Announces Sixth ANDA Submission Of 2015

      http://igilabs.investorroom.com/2015-07-23-IGI-Laboratories-…
      Avatar
      schrieb am 24.07.15 15:29:44
      Beitrag Nr. 18 ()
      IGI Laboratories Announces Second Quarter 2015 Results
      Sales Grow 37% Over 2014, Pipeline to Date Increases to 28 ANDAs on File

      BUENA, N.J., July 23, 2015 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey-based specialty generic pharmaceutical company, announced its financial results for the second quarter ended June 30, 2015.


      Second Quarter 2015 Highlights
      •Total revenues of $8.9 million in the second quarter of 2015, an increase of 37% over the same quarter in 2014
      •Total net revenues generated from the sale of IGI label generic topical pharmaceutical products for the three months ended June 30, 2015 and 2014 of $6.7 million and $3.4 million, respectively
      •Gross profit for the three months ended June 30, 2015 equaled 41% as compared to 45% in the same period in 2014
      •IGI filed four Abbreviated New Drug Applications (ANDAs) in the second quarter of 2015 with the U.S. Food and Drug Administration (FDA)
      •Operating loss was $1.9 million in the second quarter of 2015 compared to $0.3 million in the same period in 2014, primarily attributable to an increase in research and development costs of $1.4 million over the same period in 2014
      •Adjusted EBITDA (as defined and reconciled to GAAP below) for the three months ended June 30, 2015 and 2014 was $(1.2) million and $0.1 million, respectively
      •Adjusted net loss per fully diluted share (as defined and reconciled to GAAP below) for the three months ended June 30, 2015 and 2014 was $0.04 and $0.00, respectively

      Full Year 2015 Financial Guidance
      •The Company expects sequential improvement quarter over quarter in total revenue for the remainder of the year, and therefore still expects total revenue between $35.0 and $40.0 million for the year ended December 31, 2015.
      •The Company anticipates sequential improvement in gross margin quarter over quarter for the remainder of the year, and therefore expects gross margin of 45% to 50% for the year ended December 31, 2015.
      •The Company intends to submit up to 20 ANDAs with the FDA by the end of 2015. In order to complete all of the development work required for the 2015 filings, the Company continues to expect to spend between $13 and $14.5 million in research and development by the end of 2015.
      •As a result of the expected sequential increase in total revenue in the third and fourth quarters of 2015, the Company intends to improve its operating margin to approach break even in the fourth quarter of 2015, sequentially.

      IGI's President and Chief Executive Officer, Jason Grenfell-Gardner, stated, "We are pleased with our steady progress this quarter. On the regulatory front, we received the FDA's final approval for our diclofenac sodium 1.5% topical solution earlier this month. We also added another six ANDA submissions during fiscal 2015, including the submission filed today. While there have been some changes in the econazole market earlier this quarter, we have regained market share for that product again over the last two months." Mr. Grenfell-Gardner continued, "Our long-term vision continues to focus on the creation of a diversified product portfolio, built around our topical, injectable, complex and ophthalmic, or TICO, strategy. During the second quarter, we submitted a Prior Approval Supplement to the FDA for our first injectable product, and we are working hard to target the launch of that product before the end of 2015."

      Mr. Grenfell-Gardner concluded, "As of today, we have twenty-eight ANDAs pending with the FDA. Based on May 2015 IMS Health data, the addressable market for our pipeline of such twenty-eight ANDAs is estimated at $1.2 billion. We continue to see positive momentum in our correspondence with the FDA with regard to applications filed after October 1, 2014, or the third year after implementation of the Generic Drug User Fee Amendments of 2012. We are committed to responding effectively to the FDA's accelerated deadlines for applications currently under review, so we plan to submit up to a further fourteen ANDAs with the FDA this year, for a total of up to twenty new topical submissions in 2015." ...

      http://igilabs.investorroom.com/2015-07-23-IGI-Laboratories-…
      Avatar
      schrieb am 24.07.15 15:44:29
      Beitrag Nr. 19 ()
      Roth Capital: Time To Buy IGI Labs, 2016 Could Be 'Breakout Year'
      July 24, 2015 9:33am , Monica Gerson , Benzinga Staff Writer

      In a report published Friday, Roth Capital Partners analyst Scott R. Henry upgraded the rating on IGI Laboratories, Inc.
      IG 21.68%
      from Neutral to Buy, while raising the price target from $7 to $11.

      Analyst Scott R Henry cited "stabilization of the econazole nitrate franchise, a lower valuation, and potential ANDA pipeline catalysts coming out of 2015 and into 2016" as the impetus for the upgrade.

      IGI Laboratories develops, manufactures, and markets topical formulations in the US, besides developing, manufacturing, filling and packaging topical semi-solid and liquid products for the pharmaceutical and cosmetics industries.

      The company reported better-than-expected 2Q15 revenues of $8.9 million, driven by new contract wins for the econazole nitrate franchise. The company hinted at a potential stabilization of its revenue stream.

      Saying that 2016 could be a "Breakout" year for IGI Laboratories, the Roth Capital Parners report noted, "Our forecast now targets ~$16M per year from this franchise in 2016+. We expect only modest new approvals in 2015 (perhaps 1 additional product launch)."

      "However, the year 2016 could bring old ANDA approvals (could be as high as 9 launches) and new accelerated GDUFA approvals (could be as high as 5 launches). This bolus of 14 potential approvals could start the hyper revenue growth that investors have been waiting for," the report added.

      http://www.benzinga.com/analyst-ratings/analyst-color/15/07/…
      Avatar
      schrieb am 24.07.15 19:39:44
      Beitrag Nr. 20 ()
      Why Shares of IGI Laboratories, Inc. Soared Today
      IGI Laboratories stock surged more than 19% today after reporting second quarter results. Where results really good enough to justify such a strong move?

      What: Shares of IGI Laboratories (NYSE MKT:IG), a specialty generic pharmaceutical company, soared more than 22% higher this morning after the company reported second quarter earnings last night.

      So what: Revenue for the quarter jumped 37% year-over-year to $8.9 million, slightly ahead of the $8.89 million that analysts were expecting. On a GAAP basis, net loss for the quarter was -$0.04 per share, which was well ahead of the -$0.08 loss that analysts were expecting.

      The company reaffirmed revenue guidance for the full year to land between $35 and $40 million and also expects that gross margins will improve with each passing quarter. This should allow the company to approach a break-even operating margin by the fourth quarter.

      In addition, the company is planning to submit up to 20 abbreviated new drug applications, or ANDAs, to the FDA by the end of the year. An ANDA is an application for a generic drug approval for an existing licensed medication or drug.

      Now what: IGI was able to submit 6 new ANDA submissions to the FDA for approval during the quarter, bringing their total to 28 ANDAs currently pending approval. Combined, the company estimates that these 28 generic drugs represent a $1.2 billion market opportunity, which is a huge increase from the $702 million opportunity that the company was previously targeting from their ANDA submissions just last quarter.

      Although ANDAs can take a long time to get through the FDA, I think investors were right to cheer the news today, as a $1.2 billion market opportunity is simply massive for a company that is estimating full year revenue of just $35 to $40 million.

      With more than $150 million in cash on the balance sheet, the company appears to have plenty of capital to fund its research and development efforts needed to complete the additional ANDA filings. If IGI can manage to reach a break-even operating margin by the end of the year, it should put the company on solid financial footing, which could make the stock a very interesting investment opportunity, even after today's huge move.

      This $19 trillion industry could destroy the Internet
      One bleeding-edge technology is about to put the World Wide Web to bed. And if you act quickly, you could be among the savvy investors who enjoy the profits from this stunning change. Experts are calling it the single largest business opportunity in the history of capitalism... The Economist is calling it "transformative"... But you'll probably just call it "how I made my millions." Don't be too late to the party -- click here for one stock to own when the Web goes dark.

      http://www.fool.com/investing/general/2015/07/24/why-shares-…
      Avatar
      schrieb am 24.07.15 19:52:49
      Beitrag Nr. 21 ()
      ein Schlusskurs über 8$ wäre schon ne feine Sache
      Avatar
      schrieb am 24.07.15 20:02:47
      Beitrag Nr. 22 ()
      nach den Zahlen zum ersten Quartal ging es von 7,95$ auf 5,20$. Nun sieht der Chart schon nicht mehr so schlimm aus.

      Einfaches Einfügen von wallstreetONLINE Charts: So funktionierts.


      Einfaches Einfügen von wallstreetONLINE Charts: So funktionierts.


      Man könnte schon fast einen Aufwärtstrend erkennen
      Avatar
      schrieb am 24.07.15 20:35:40
      Beitrag Nr. 23 ()
      IGI Laboratories' (IG) CEO Jason Grenfell Gardner on Q2 2015 Results - Earnings Call Transcript

      kleiner Auszug
      ...
      Operator

      Our next question comes from Scott Henry of ROTH Capital.

      Scott Henry - ROTH Capital
      And for clarification, it was 53% in Q1. I just checked the 10-Q. Just a couple of questions. I guess, Jason, it sounds like Econazole Nitrate, the outlook improved during the quarter versus your baseline expectations and you did maintain revenue guidance. Is the guidance more conservative now would you say? I mean, you were more optimistic given -- I'm just trying to get a sense of how much that improvement carries throughout the rest of the year?

      Jason Grenfell Gardner - President and Chief Executive Officer
      I mean, we go through a process of looking at this forecast on a regular basis. And while we've been able to pick up some share on Econazole to help us through this quarter, this is still not something that I feel totally concrete about. And I always like to see a few weeks of sale, a few months of sales, so little bit of continuity and a little bit of stability at the market as well as continued predictability from the market channel to have that good feeling.

      So with Econazole being a specific part of that forecast that little bit of variability that we've just gone through makes me a little bit more circumspect about trying to increase the forecast beyond where we are. Having gone through that forecasting exercising on pre-granular basis, we feel good about where we are that 35% to 40%, and I think we're going to stick with that.

      Scott Henry - ROTH Capital
      And when I look at the weekly prescription data, I mean is the product basically held up at 24% to 25% share? And then just the last week it dipped down to 21%. Is this data, kind of severely dated, I mean do you think this there is a lag in it? I'm just wondering if the weekly data is of much use in the current dynamics.

      Jason Grenfell Gardner - President and Chief Executive Officer
      Yes. I mean I think whenever you go through some of these big market changes, the data lags. If you go back and look at some of that script data from couple of years ago, you would have continued to see [indiscernible] script even though we knew that there wasn't [indiscernible] inventory in the channel. So depending on what the reporting sources are there is certainly a lag there that impacts how quickly you see the changes in the underlying data.

      Scott Henry - ROTH Capital
      And then I guess it will be for Jen. The comment about operating margin approaching breakeven in the fourth quarter '15. Should I just think about that as the operating profit line before any interest expense or anything below that line?

      Jenniffer Collins - Chief Financial Officer
      That's correct, Scott.

      Scott Henry - ROTH Capital
      And would you expect to be able to maintain that kind of breakeven-ish operating profit into 2016, I would certainly expect given the approvals, but just want to get your thoughts?

      Jenniffer Collins - Chief Financial Officer
      I mean obviously, we're not talking about '16 guidance here, but I think our expectation is as we continue to get approvals, we continue to grow share that there would be improvement from our breakeven margin into 2016, that certainly is a goal. Again, the major driver there is going to be R&D cent.

      Scott Henry - ROTH Capital
      And certainly Econazole Nitrate would be at a steady state by fourth quarter.
      ...

      http://seekingalpha.com/article/3353125-igi-laboratories-ig-…
      Avatar
      schrieb am 30.07.15 16:59:46
      Beitrag Nr. 24 ()
      Antwort auf Beitrag Nr.: 48.733.739 von b1homann am 09.01.15 11:55:37Habe jetzt mal die Gewinne mitgenommen.
      Andererseits - Zacks ratet immer noch (oder wieder?) mit 1.
      Denke, dass man wieder billiger rein kommt.
      Avatar
      schrieb am 25.10.15 15:28:46
      Beitrag Nr. 25 ()
      einiges los bei IG / Teligent

      IGI Laboratories, Inc. Enters Into Agreement To Acquire The Assets Of Canadian Pharmaceutical Company, Alveda Pharmaceuticals, Inc.
      Oct 13, 2015
      http://teligent.investorroom.com/2015-10-13-IGI-Laboratories…

      IGI Laboratories Announces Approval For Listing On The NASDAQ Global Select Market
      Oct 14, 2015
      http://teligent.investorroom.com/2015-10-14-IGI-Laboratories…

      IGI Laboratories Announces Third Quarter 2015 Results
      Oct 22, 2015

      -Sales Grow 74% Over 2014 and 31% Over Second Quarter 2015
      -Submits Tenth ANDA in 2015
      http://teligent.investorroom.com/2015-10-22-IGI-Laboratories…

      IGI Laboratories, Inc. Announces Name Change To Teligent, Inc.
      Oct 22, 2015
      http://teligent.investorroom.com/2015-10-22-IGI-Laboratories…


      ab morgen dann also unter TLGT zu finden.
      http://finance.yahoo.com/q?s=tlgt&ql=1

      hier die HP http://www.teligent.com/

      hab am Freitag nochmal nachgelegt, auch wenn der BIO-Sektor zur Zeit keinen Spaß macht.

      Sollte noch einer da sein, viel Erfolg und schönes Wochenende
      Avatar
      schrieb am 25.10.15 15:43:08
      Beitrag Nr. 26 ()
      Ergänzung

      IGI Laboratories, Inc. Announces Acquisition Of Three Commercialized Injectable Products
      Oct 5, 2015
      http://teligent.investorroom.com/2015-10-05-IGI-Laboratories…

      Stephen Richardson Appointed As Chief Scientific Officer Of IGI Laboratories, Inc.
      Oct 5, 2015
      http://teligent.investorroom.com/2015-10-05-Stephen-Richards…
      Avatar
      schrieb am 11.12.15 15:32:10
      Beitrag Nr. 27 ()
      Teligent, Inc. Announces Eleventh ANDA Submission Of 2015
      BUENA, N.J., Dec. 1, 2015 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, today announced it has submitted its eleventh abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA) of 2015, which brings the Company's total number of ANDA submissions now pending at the FDA to twenty-nine.
      http://teligent.investorroom.com/2015-12-01-Teligent-Inc-Ann…
      Avatar
      schrieb am 11.12.15 15:34:46
      Beitrag Nr. 28 ()
      Teligent, Inc. Announces FDA Approval Of CEFOTAN® (cefotetan) For Injection
      Product Launch in Early 2016 Will Address Current Drug Shortage

      BUENA, N.J., Dec. 11, 2015 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's supplemental new drug application (sNDA) from the U.S. Food and Drug Administration (FDA) for CEFOTAN® (cefotetan) for Injection. This is the Company's first product approved from the portfolio of discontinued and withdrawn new drug applications (NDAs) and abbreviated new drug applications (ANDAs), which the Company purchased from Astra Zeneca on September 25, 2014.
      http://teligent.investorroom.com/2015-12-11-Teligent-Inc-Ann…
      Avatar
      schrieb am 12.07.16 18:36:20
      Beitrag Nr. 29 ()
      Teligent, Inc. Receives Two FDA Approvals For Topical Prescription Portfolio
      Represent the Fifth and Sixth FDA Approvals of the Year, Launches Planned for This Quarter
      Jul 8, 2016
      http://teligent.investorroom.com/2016-07-08-Teligent-Inc-Rec…

      es geht voran
      Avatar
      schrieb am 29.07.16 15:26:18
      Beitrag Nr. 30 ()
      Teligent, Inc. Announces Second Quarter 2016 Results
      Teligent Product Revenue Growth of 66% Over 2015, Driven by Diversified Launches
      Jul 28, 2016

      http://teligent.investorroom.com/2016-07-28-Teligent-Inc-Ann…
      Avatar
      schrieb am 23.08.16 17:33:57
      Beitrag Nr. 31 ()
      Teligent, Inc. Announces Health Canada Approval Of Gentamicin Injection USP
      Aug 23, 2016

      http://teligent.investorroom.com/2016-08-23-Teligent-Inc-Ann…
      Avatar
      schrieb am 25.08.16 15:16:45
      Beitrag Nr. 32 ()
      Teligent, Inc. Announces Health Canada Approval Of Three Baclofen Injection Products
      Aug 25, 2016

      http://teligent.investorroom.com/2016-08-25-Teligent-Inc-Ann…
      Avatar
      schrieb am 30.09.16 10:07:53
      Beitrag Nr. 33 ()
      Teligent is a specialty generic drug manufacturer with expertise in the topical, injectable, complex, and ophthalmic markets. Each year, a number of drugs in these categories lose patent protection, and Teligent swoops in to create copycat versions, win FDA approval, and then sell them at steep discounts.
      This business model is working out beautifully for shareholders. Sales grew by a huge 93% last quarter, and the company even managed to eke out a small profit. Teligent's backlog also continues to grow;  it currently has 33 products awaiting FDA review. In total, the company believes that these drugs represent an addressable market opportunity of $1.6 billion. That sets the stage for continued fast growth. 
      Looking ahead, analysts are calling for nearly 40% revenue growth next year and for the company's profits to triple. With the wind at its back, I think Teligent should be able to grow at above-average rates for years to come, so count me as a bull.

      http://www.fool.com/investing/2016/09/29/3-top-stocks-under-…


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.
      IGI Laboritories - Unglaubliches Kursziel von Credit Suisse